Hsu JL, Lee WJ, Liao YC, Wang SJ, Fuh JL. The clinical significance of plasma clusterin and Aβ in the longitudinal follow-up of patients with Alzheimer's disease. Alzheimers Res Ther. 2017 Nov 23;9(1):91. PubMed.

AlzBiomarker Database

Meta-Analysis

Curated Study Data

Biomarker
(Source)		 Cohort
(N)		 Measurement
Mean ± SD		 Method;
Assay Name;
Manufacturer		 Diagnostic
Criteria
Aβ40
(Plasma)		 AD
(322)		 157.9 ± 50.7
pg/mL		 xMAP;
INNO-BIA plasma Aβ forms assay;
Fujirebio		 McKhann et al., 2011
Aβ40
(Plasma)		 CTRL-
CNC
(88)		 144.5 ± 36.9
pg/mL		 xMAP;
INNO-BIA plasma Aβ forms assay;
Fujirebio
Aβ42
(Plasma)		 AD
(322)		 36.9 ± 20.8
pg/mL		 xMAP;
INNO-BIA plasma Aβ forms assay;
Fujirebio		 McKhann et al., 2011
Aβ42
(Plasma)		 CTRL-
CNC
(88)		 34.1 ± 9.1
pg/mL		 xMAP;
INNO-BIA plasma Aβ forms assay;
Fujirebio

Recommends

Please login to recommend the paper.

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

AlzBiomarker

  1. AD vs CTRL : Aβ40 (Plasma and Serum)
  2. CTRL vs AD : Aβ40 (Plasma and Serum)
  3. AD vs CTRL : Aβ42 (Plasma and Serum)
  4. CTRL vs AD : Aβ42 (Plasma and Serum)